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Purpose: Pressurized metered dose inhalers are commonly used in
patients with asthma. However, the need to coordinate inhalation
with inhaler actuation means that they are not suitable for use per se.
Valved holding chamber devices were developed to overcome some
of the problems of pressurized metered dose inhalers. Several types
of holding chambers of different sizes are available in Iran. This
study was designed to compare the effects of 2 commonly used
valved holding chambers (Asthm Yar and Dam Yar) in Iran on
bioavailability of salbutamol spray and also spirometric parameters
in asthmatic patients.
Methods: This was a comparative experimental crossover study.
Patients with mild to moderate asthma were entered in this study.
Lung function was assessed using a portable spirometer (Spirolab,
Progetti, Italy). Spirometric parameters of forced expiratory ﬂow
(FEF)50%, FEF25–75%, peak expiratory ﬂow (PEF), forced expiratory
volume in the ﬁrst second of expiration (FEV1), forced vital capacity
(FVC), and FEV1/FVC were measured. Urinary concentration of
salbutamol as an index of pulmonary bioavailability was assayed
with high-performance liquid chromatography.
Results: Forty patients (25 women and 15 men) with the mean age
of 43.10 6 12.99 years were studied. Mean 6 SD changes of spi-
rometric parameters before and after using Asthm Yar were not
signiﬁcantly different from those of Dam Yar. The relative bioavail-
ability after inhalation with Asthm Yar was signiﬁcantly higher than
after inhalation with Dam Yar (P ¼ 0.002).
Conclusions: Although the results indicate that relative bioavail-
ability to the lung after inhalation with Asthm Yar was signiﬁcantly
higher than after inhalation with Dam Yar, its clinical importance
should be tested.
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The majority of asthmatic patients continue to use pressurizedaerosol metered dose inhalers (pMDIs).1–3 The need to
coordinate inhalation and actuation of inhalers is an important
issue.3 Valved holding chambers are introduced to overcome
this problem.4 It has been shown that inhalation therapy using
a pMDI with a valved holding chamber plays a crucial role in
the treatment of asthmatic patients.3,5 The advantage of drug
delivery with valved holding chambers in asthmatic patients is
due to their simplicity in use compared with pMDIs without
valved holding chambers.6 They allow the patients to breathe
from a pool of the drug. Also, valved holding chambers decrease
the amount of medication deposited in the oropharynx.7,8
Finally, valved holding chambers increase the delivery of drug
to its target (ie, lungs) while minimizing oral absorption.9,10
Several kinds and diverse sizes of holding chamber are
obtainable in the market (eg, Aerochamber, Babyhaler, and
Volumatic). Asthm Yar and Dam Yar are 2 frequently used
valved holding chambers in Iran. There is no convincing
study on the efﬁcacy of valved holding chambers with
diverse sizes.11,12 Measurements of the lung function were
used to compare the efﬁcacy. Furthermore, the concentration
of drug excreted in the urine during the ﬁrst 30 minutes after
the start of an inhalation is determined for evaluating the
differences in systemic bioavailability. Salbutamol depos-
ited in the lungs is immediately delivered to the systemic
circulation and excreted in the urine.13 Assessing relative
bioavailability of salbutamol to the lung by obtaining a urine
sample 30 minutes after an inhalation is reproducible, sim-
ple, and effective.14 The advantages of this method in com-
parison with others is using the patient’s own inhaler, no
need for either the ingestion of charcoal or the use of
a radiolabel-inhaled marker. Furthermore, it could be used
concomitantly with the measurement of the lung function to
show the correlation between improved deposition and
enhanced spirometry.13
Thus, the main objective of this study was to compare
urinary salbutamol concentration as a measure of relative
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bioavailability to the lung via the 2 valved holding chambers.
Also, clinical efﬁcacy in terms of spirometric parameters with
the 2 devices was also evaluated.
MATERIALS AND METHODS
Study Subjects and Setting
Patients who referred to the pulmonary clinic of
NRITLD (National Research Institute for Tuberculosis and
Lung Disease), Masih Daneshvari Hospital, between the age
range of 18 and 60 years were evaluated for study eligibility.
The study was approved by Ethical Committee of the Shahid
Beheshti University of Medical Sciences. Diagnosis of
asthma was made according to the Global Initiative for
Asthma deﬁnition.15
Patients were excluded if they had severe asthma,
chronic obstructive pulmonary disease, and renal dysfunction
(serum creatinine, .1.2 mg/dL or ,0.6 mg/dL). Also, smok-
ers and pregnant women, and those who were noncompliant
to the study protocol, were excluded. All asthma medications
except corticosteroid inhalers were discontinued for at least
12 hours before the study.
Study Design
This was a comparative experimental study, which was
approved by the Drug and Therapeutic Committee of the
Hospital and the Ethics Committee of the Shahid Beheshti
University of Medical Sciences, Tehran, Iran. Written consent
was obtained from each patient.
The valved holding chamber devices used in this study
were consistent with a polycarbonate volumatic (750 mL,
Asthm Yar; Farafan Engineering Company, Tehran, Iran)
(Fig. 1) and a polycarbonate nonvolumatic (140 mL, Dam
Yar; Fanava Teb Espadana Co, Isfahan, Iran) (Fig. 2) valved
holding chambers. Salbutamol 100 mg per dose pMDIs
(Ventalex HFA, Sina Daru, Iran) was used with each valved
holding chamber. The washing method was based on what
Mazhar and Chrystyn12 have proposed in their study. The
valved holding chambers were washed in warm mild deter-
gent, soaked in water, and left to air dry before use. The
patients used the devices with mouthpieces.
The ﬁrst 2 actuations from each pMDIs were ﬁred
(primed before use). The pMDIs were pressed ﬁrmly into the
valved holding chambers.
Patients were educated to exhale the functional
residual capacity before actuation, then to inhale slowly
and deeply to total lung capacity in 5 to 10 seconds after
which hold the breath for 10 seconds,14 and they practiced
the correct inhalation technique of the valved holding
chamber used at each step. Four doses of salbutamol were
then inhaled via the valved holding chamber (volumatic or
nonvolumatic). Subjects voided urination 15 minutes before
dosing and then provided a urine sample 30 minutes after
the ﬁrst inhalation.16 Because urinary excretion is the main
route of elimination for both unchanged salbutamol and its
sulfate conjugate, quantization of the urinary excretion of
salbutamol offers a noninvasive method for determining the
bioavailability of the drug using different valved holding
chambers.17 In addition, the urinary assay is extremely pre-
cise for salbutamol and its conjugate. So, this methodology
provides a reliable technique for assessing aerosol delivery
and relative lung bioavailability in asthmatic patients.17
Patients were instructed to maintain their normal ﬂuid
intake. Spirometry was performed 10 minutes after the
inhalation.
For bioavailability analysis, each patient was trained
to inhale 4 actuations of salbutamol (400 mg) via Asthm Yar
and Dam Yar separately. Patients were randomly assigned
to use each of the 2 devices at the ﬁrst phase, and the other
one in the second phase of the study. Urine samples were
kept in refrigerator (2208C) until analysis with high-perfor-
mance liquid chromatography (HPLC). The person who
assayed salbutamol level in urine was blind to the study
protocol. The subjects used Dam Yar on the ﬁrst week (ﬁrst
phase) and then crossed over to Asthm Yar on the second
week (second phase).FIGURE 1. Asthm Yar.
FIGURE 2. Damyar.
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Spirometric Parameters With Valved
Holding Chambers
The change in forced expiratory volume in the ﬁrst second
of expiration (FEV1) 10 minutes after salbutamol inhalation was
the primary outcome measure. Measurements were performed
by means of Spiro lab II (Medical International Research, Via
del Maggiolino, Italy). Individual predicted FEV1 values were
recorded according to the patient characteristics. All measure-
ments were performed by a trained investigator. We calculated
the absolute change in values from initial prebronchodilator
value. Three measurements were achieved for each patient,
and the best one was used in data analysis. Other spirometric
parameters that were quantiﬁed in the study were forced expi-
ratory ﬂow (FEF)50%, FEF25–75%, peak expiratory ﬂow (PEF),
forced vital capacity (FVC), and FEV1/FVC. All the spirometric




Salbutamol sulfate, the United States Pharmacopeia
reference standard, was a donation from Exir Pharmaceutical
Company. The internal standard epinephrine hydrochloride
was obtained from Daru Pakhsh Company. HPLC grade
methanol was used in all the analyses. Ultra pure bioreagent
grade sodium dodecyl sulfate and potassium dihydrogen
phosphate were purchased from Fluka.
Instruments and Conditions
The HPLC system consisted of a pump, an auto sampler,
a ﬂuorescence detector, and a computer system. Also used
was a C-18 reversed phase 4.6 · 250-mm analytical column
(Waters Symmetry C18; Waters Corp, Milford, MA) and
a C-18 3.9 · 20-mm guard column (Waters Sentry Guard
Column; Waters Corp, Milford, MA). The mobile phase
was composed of methanol and water (60:40 vol/vol) con-
taining 10 mM potassium dihydrogen phosphate and 20 mM
sodium dodecyl sulfate as an ion-pair reagent. The mobile
phase was adjusted at a pH of 2.95 with 1.0 M phosphoric
acid. The ﬂow rate was 1.2 mL/minute, and detection wave-
lengths were 276 nm for excitation and 609 nm for emission.
Standard Preparation
Duplicate spiked urine standards were prepared at
6 different concentrations using 2 independently prepared
stock solutions (A and B) to cover the sample analysis, which
ranged from 250 to 2000 ng/mL.
Sample Preparation
The urine sample (1 mL) was added to a 10-mL glass
centrifuge tube containing 2 mL of 0.1N hydrochloric acid.
The tube was capped with a screw top and then was placed in
a boiling water bath for 30 minutes. After cooling, an aliquot
of 2 mL of 0.1N sodium hydroxide was added to the sample
and vortexed. An aliquot of 10 mL of epinephrine hydrochlo-
ride internal standard working stock solution (2.5 mg/10 mL)
was added to the resulting solution. The mixture was vortexed
and then extracted as described below.19
Solid-phase silica cartridges were used to extract the urine
samples before analysis of the drug and metabolites. The
cartridges were prepared in-house by packing silica gel
(40–60 mm) into Pasteur pipettes. Glass beads (2.5 mm) were
placed at the tip of the Pasteur pipette to act as the bed support,
followed by the silica gel (100-mg dry weight) to form a bed
depth of approximately 25 mm. The cartridges were conditioned
by eluting with 2 mL of methanol under gravity and then wash-
ing with 2 mL of water. The urine samples (1 mL) containing the
drug and epinephrine as the internal standard were loaded on to
the cartridges, which were then washed with 2 mL of water
before altering the polarity of the eluting solvent by washing with
1 mL of methanol. The eluate was evaporated to dryness with
a stream of oxygen-free nitrogen at room temperature. The res-
idue was reconstituted with 250-mL HPLC mobile phase, and
a 100-mL sample was injected onto the chromatographic column.
The system was validated for accuracy, precision, and linearity.19
Calculations
Standard curves were generated by plotting peak-area
ratios (salbutamol/internal standard) as a function of salbutamol
concentration and by least-squares linear regression analysis for
the line of best ﬁt. The ﬁnal concentration represented the sum
of both unchanged salbutamol and its sulfate conjugate.
Statistical Analysis
The analysis of data was performed using statistical
package for social sciences (SPSS 17; SPSS, Inc, Chicago,
IL). The results were expressed as mean 6 SD, and the Stu-
dent t test and the paired t test were applied for demographic
and spirometric data comparisons. P values of ,0.05 were
regarded as signiﬁcant.
RESULTS
Forty patients (25 women and 15 men) with a mean 6
SD age of 43.10 6 12.99 years were recruited. Table 1 illus-
trates detailed demographic data and spirometric results
obtained in this study.
There was a signiﬁcant improvement in the mean
spirometric parameters after using each valved holding
chamber (P , 0.05). However, no signiﬁcant difference
was observed between the 2 valved holding chambers in
terms of spirometry improvements.
The concentration of salbutamol recovered in the
urine was 1188.84 6 478.80 ng/mL using Asthm Yar and
926.68 6 351.95 ng/mL using Dam Yar. The percentage
of drug excreted differed signiﬁcantly between the 2 groups
(P ¼ 0.002) (Fig. 3; Table 1).
DISCUSSION
To assess if valved holding chambers’ volume or size
has a role in clinical practice, the response to 400 mg of sal-
butamol administered by small volume valved holding cham-
ber (Dam Yar) was compared with that obtained with the same
dose administered with large volume valved holding chamber
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(Asthm Yar), which are the 2 commonly used valved holding
chambers in Iran. Asthm Yar is more bulky compared with
Dam Yar, which has a smaller volume, thus is inconvenient to
use and carry around.20 The urinary excretion of salbutamol in
patients reﬂects the systemic absorption of the drug deposited
in the lower respiratory tract. Furthermore, the urinary assay is
highly speciﬁc for salbutamol and its conjugate.14 After 1 and 2
doses of salbutamol from Easibreath in asthmatic patients, the
results of measurements of 30-minute urinary salbutamol and
the dose of methacholine to reduce the FEV1 by 20% were in
concordance.21 The equivalency of these 2 methods and the
reproducibility showed that the 30 minutes could be used as an
index of lung deposition. These results also conﬁrm the vital
role of pharmacokinetic studies in determining the bioequiva-
lence of inhaled products.22
Based on the results of this study, the amount of excreted
salbutamol in the urine 30 minutes after inhalation with Asthm
Yar (1188.84 6 478.80 ng/mL) shows signiﬁcant difference
(P ¼ 0.002) in comparison with that excreted after inhalation
with Dam Yar (926.68 6 351.95 ng/mL). Therefore, large vol-
ume spacer delivered more drug than smaller one. These results
are in consistence with the available reports on better drug




Age (yr) 43.10 6 12.99 Male: 44.93 6 14.07 0.71
Female: 43.32 6 12.56
Gender N ¼ 40 Male: 15 NA
Female: 25
Weight (kg) 68.53 6 13.38 Male: 73.27 6 9.26 0.08
Female: 65.68 6 14.79
Height (cm) 163.33 6 7.91 Male: 170.45 6 7.70 ,0.0001*
Female: 159.04 6 4.00
FVC† difference‡ 5.34 6 7.45 Asthm Yar: 4.75 6 6.99 0.46
Dam Yar: 6.05 6 8.00
FEV1† difference ‡ 7.39 6 5.49 Asthm Yar: 7.54 6 5.08 0.53
Dam Yar: 7.23 6 5.93
PEF† difference‡ 4.18 6 13.52 Asthm Yar: 7.10 6 13.64 0.054
Dam Yar: 1.25 6 12.92
FEF25–75%† difference‡ 16.20 6 12.49 Asthm Yar: 16.30 6 12.05 0.92
Dam Yar: 16.10 6 13.06
FEF50%† difference‡ 13.94 6 11.55 Asthm Yar: 13.45 6 11.78 0.64
Dam Yar: 14.43 6 11.44
Preference 6.00 6 2.58 Asthm Yar: 4.83 6 2.38 ,0.0001*
Dam Yar: 7.18 6 2.23
SUC (ng/mL)§ Mean: 1057.76 6 437.86 Asthm Yar 0.002*








†As percentage of the predicted values.
‡Before and after spacer use.
§Salbutamol urine concentration.
FEF, forced expiratory ﬂow; PEF, peak expiratory ﬂow; FVC, forced vital capacity.
FIGURE 3. Urinary salbutamol concentration (mean 6
standard error) after inhalation via Dam Yar (spacer1) and
Asthm Yar (spacer 2).
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delivery by higher volume spacers.10 Several in vitro and in vivo
studies have shown that different factors affect the dose delivered
from a holding chamber and may be responsible for this poor
efﬁciency.23,24 These include chamber size, shape, resistance of
the valve, dead volume, the use of multiple actuations, inhalation
delay, and construction materials, which have inﬂuence on the
levels of electrostatic charge in the chamber. Electrostatic charge
is intrinsic to every plastic device, including plastic spacers, as
a result of their nonconducting properties. The charge varies in
a random style. The net effect of electrostatic charge is the
absorption of aerosol particles onto plastic surfaces of the spacers,
leading to a noteworthy reduction in the initial dose available for
inhalation and hence the lung dose.25 Approximately 90% of the
dose is dumped and swallowed in the oropharyngeal system
using pMDIs. However, using spacers would result in the
reduction of particle velocity during inspiration and therefore
decreases the systemic bioavailability of the drug.10 Perhaps,
Asthm Yar is more efﬁciently designed that its electrostatic
charge might have been less than Dam Yar. Although this
hypothesis should be conﬁrmed in the future studies, as men-
tioned before, these devices were static and washed before use.
In a study by Lipworth and Clark26 in 1998, salbutamol
inhalation dose as a MDI was measured via 3 common plastic
spacers (Nebuhaler, Volumatic: large volume, and Aerocham-
ber: small volume). The results demonstrated that the large
volume spacer (Volumatic) had more drug delivery to the lungs
in comparison with Aerochamber and Nebuhaler or using the
MDI alone.26 Furthermore, Mazhar and Chrystyn12 have com-
pared Volumatic (VOL) and Aerochamber Plus VHC (AERO).
Data conﬁrmed that Volumatic was more efﬁcient, although
the difference was very small. However, our results are con-
sistent with their ﬁndings. The increased bioavailability of sal-
butamol using large volume spacers may be of special interest
in patients with poor inhalation technique that could result in
improved lung function in this population.14 Nevertheless, this
ﬁnding is not consistent in all the studies. In 2005, Walker and
Owen20 assessed the effect of spacer volume on drug delivery
to children using pressurized inhalers. Unexpectedly, small
volume spacer delivered more drug than large volume spacer.
It is believed that this is possibly due to the more efﬁcient
construction and design of the Aerochamber, as the delivery
is normally improved when using large volume spacers.20
In conclusion, although the results indicated that
relative bioavailability to the lung after inhalation with Asthm
Yar was signiﬁcantly higher than that after inhalation with
Dam Yar, its clinical importance should be tested.
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